OncoMatch

OncoMatch/Non-Hodgkin Lymphoma (NHL)/MYC rearrangement

Non-Hodgkin Lymphoma (NHL)MYC rearrangement Clinical Trials

20 recruiting trials·Updated daily from ClinicalTrials.gov

MYC rearrangements define Burkitt lymphoma (near-universally) and high-grade B-cell lymphoma (double/triple-hit with BCL2/BCL6) among NHL subtypes, and confer aggressive biology and poor outcomes with standard regimens. Intensive regimens (R-CODOX-M/IVAC, DA-EPOCH-R) are used in MYC-rearranged aggressive NHL. Trials investigate first-line CAR-T therapy, polatuzumab vedotin combinations, and novel MYC-directed approaches for this unmet-need population.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting MYC rearrangement Non-Hodgkin Lymphoma (NHL) trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Nordic Lymphoma Group

Phase 284 US sites

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

National Cancer Institute (NCI)

Phase 231 US sites

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 230 US sites

DALY II USA/ MB-CART2019.1 for DLBCL

Miltenyi Biomedicine GmbH

Phase 27 US sites

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 24 US sites

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Additional trials

More MYC rearrangement Non-Hodgkin Lymphoma (NHL) trials

Phase 2
NCT05256641Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaPhase 1/Phase 23 US sitesNCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GenePhase 1/Phase 22 US sitesNCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaPhase 21 US siteNCT06249191Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell LymphomaPhase 1/Phase 21 US siteNCT06687772CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantPhase 21 US site
9 international trials (no US sites)
NCT04661020CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell LymphomaPhase 2NCT06558604Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaPhase 2NCT06486051A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell LymphomaPhase 2NCT06891157Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular SubtypesPhase 2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLPhase 2NCT04836507Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia PatientsPhase 1/Phase 2NCT06764017CHiR Therapy for Elderly DLBCL Intolerant to ChemoPhase 2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLPhase 2NCT06208735CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesPhase 1
Other Non-Hodgkin Lymphoma (NHL) biomarkers

Browse other molecular targets with active Non-Hodgkin Lymphoma (NHL) trials.

PD-L1 (CD274)
← All Non-Hodgkin Lymphoma (NHL) clinical trials